-
Tempest Weighs M&A, Analyst Sees A "Broken Story" Despite Phase 2 Liver Cancer Study Success
Thursday, April 10, 2025 - 12:00pm | 536Read More...Tempest Therapeutics, Inc. (NASDAQ:TPST) said on Thursday it had retained MTS Health Partners as a financial advisor. The company plans to explore strategic alternatives to advance its clinical-stage programs and maximize stockholder value. Strategic alternatives may include M&A, partnerships,...
-
Christopher Boerner To Take The Helm At Bristol Myers Squibb As Chair Of The Board, CEO
Tuesday, October 31, 2023 - 9:09pm | 482Read More...Bristol Myers Squibb (NYSE:BMY) has named Christopher Boerner as their new Chair of the Board of Directors and CEO. Boerner, who is set to take over as Chair in April 2024, will assume the role of CEO from November 1. What Happened: The pharmaceutical giant announced on October 31 that Boerner was...
-
Earnings Expectations for the Week of January 23
Sunday, January 22, 2012 - 3:13pm | 1531Read More...The earnings crunch rolls on this week. Among those scheduled to step into the spotlight are Apple (NASDAQ: AAPL), Caterpillar (NYSE: CAT), Chevron (NYSE: CVX), McDonald's (NYSE: MCD) and Starbucks (NASDAQ: SBUX). Analysts expect them post year-over-year earnings growth. AT&T (NYSE: T), Boeing...
-
Earnings Expectations for the Week of July 25
Sunday, July 24, 2011 - 9:40am | 1439Read More...The earnings crunch continues this week even as the month of July winds to a close. Quarterly reports of note scheduled for the week include those from Netflix (NASDAQ: NFLX), United Parcel Service (NYSE: UPS), Exxon Mobil (NYSE: XOM), Starbucks (NASDAQ: SBUX), Merck (NYSE: MRK) and Dow Chemical (...
-
Morgan Stanley Provides Color on Bristol Myers Squibb
Thursday, June 30, 2011 - 8:46am | 136Read More...Morgan Stanley Provided Color on Bristol Myers Squibb (NYSE: BMY). In a research report published today, Morgan Stanley states, “We expect 2013 EPS guidance to remain unchanged at minimum $1.95. In conjunction with long-term strategic planning in June, we expect Bristol to update its 2013...
-
Morgan Stanley Provides Color on Bristol Myers Squibb
Monday, June 27, 2011 - 8:03am | 134Read More...Morgan Stanley provided color on Bristol Myers Squibb (NYSE: BMY). In a research report published today, Morgan Stanley commented on the performance of the company's drug dapagliflozin. In the report, Morgan Stanley states, “Dapagliflozin (SGLT2 for diabetes) showed numerically higher bladder...
-
J.P. Morgan Maintains Neutral on Bristol Myers Squibb
Thursday, June 23, 2011 - 9:44am | 138Read More...J.P. Morgan is out with its report today on Bristol Myers Squibb (NYSE: BMY), maintaining Neutral. In a note to clients, J.P. Morgan writes, "Bristol and Pfizer (NYSE: PFE) today released very positive top-line results of the key phase III ARISTOTLE trial comparing apixaban to warfarin in patients...
-
Morgan Stanley Provides Color on Johnson & Johnson, Equal-Weight
Thursday, June 23, 2011 - 7:18am | 138Read More...Morgan Stanley provided color on Johnson & Johnson (NYSE: JNJ). In a research report published today, Morgan Stanley commented on the company's new product Xarelto. In the report, Morgan Stanley states, "Positive apixaban data in the ARISTOTLE trial may decrease commercial potential for J...
-
J.P. Morgan Provides Color on Bristol Myers Squibb and Pfizer
Tuesday, June 7, 2011 - 6:39am | 308Read More...J.P. Morgan provided color on Bristol Myers Squibb (NYSE: BMY) and Pfizer (NYSE: PFE). In a research report published today, J.P. Morgan commented on the companies' new drugs. J.P. Morgan is more impressed by Pfizer at the moment. In the report, J.P. Morgan states on BMY's Yervoy, "meaningful...
-
Goldman Sachs Downgrades Bristol-Myers Squibb To Neutral, $32 PT
Wednesday, May 11, 2011 - 5:54am | 25Read More...Goldman Sachs has downgraded Bristol-Myers Squibb (NYSE: BMY) from Buy to Neutral and maintains its $32 price target.
-
Bristol-Myers Downgraded To Sell
Friday, September 24, 2010 - 8:41am | 41Read More...Bristol-Myers Squibb (NYSE: BMY) has been downgraded to Sell by Hapoalim Securities based on the fact that the company is currently trading at just 21% above the $23 price target. Bristol-Myers Squibb closed yesterday at $27.68.
